Leerink analyst Richard Newitter raised his price target on Globus Medical shares to $65 from $61 citing the company’s accelerating core U.S. spine results and higher 2018 outlook. He said the Q3 results and raised outlook increase his confidence that Globus is on a sustained double-digit revenue growth trajectory in 2018 and beyond. Newitter reiterated an Outperform rating on Globus Medical shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.